
Gershon Golomb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5922389/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liposomal siRNA Formulations for the Treatment of Herpes Simplex Virus-1: In Vitro Characterization of Physicochemical Properties and Activity, and In Vivo Biodistribution and Toxicity Studies. Pharmaceutics, 2022, 14, 633.	4.5	5
2	Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. Nature Communications, 2022, 13, .	12.8	11
3	Targeting and imaging of monocyte-derived macrophages in rat's injured artery following local delivery of liposomal quantum dots. Journal of Controlled Release, 2020, 318, 145-157.	9.9	13
4	Liposomes of Quantum Dots Configured for Passive and Active Delivery to Tumor Tissue. Nano Letters, 2019, 19, 5844-5852.	9.1	38
5	Monocyte Modulation by Liposomal Alendronate Improves Cardiac Healing in a Rat Model of Myocardial Infarction. Regenerative Engineering and Translational Medicine, 2019, 5, 280-289.	2.9	2
6	Targeted siRNA Nanoparticles for Mammary Carcinoma Therapy. Cancers, 2019, 11, 442.	3.7	12
7	Cardiovascular delivery of drugs and biotherapeutics. Drug Delivery and Translational Research, 2018, 8, 865-867.	5.8	1
8	The role of monocyte subpopulations in vascular injury following partial and transient depletion. Drug Delivery and Translational Research, 2018, 8, 945-953.	5.8	9
9	Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases. Drug Delivery and Translational Research, 2018, 8, 868-882.	5.8	22
10	Lysozyme transport to the brain by liposomes. Precision Nanomedicine, 2018, 1, 146-161.	0.8	3
11	Delivery of Liposomal Quantum Dots <i>via</i> Monocytes for Imaging of Inflamed Tissue. ACS Nano, 2017, 11, 3038-3051.	14.6	38
12	Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model. Biomaterials, 2017, 145, 154-167.	11.4	24
13	Liposomal temozolomide drug delivery using convection enhanced delivery. Journal of Controlled Release, 2017, 261, 138-146.	9.9	63
14	Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV. Journal of Controlled Release, 2016, 229, 163-171.	9.9	70
15	Effects of radical oxygen species and antioxidants on macrophage polarization. , 2015, , .		2
16	Technical Advance: Liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease. Journal of Leukocyte Biology, 2014, 96, 491-501.	3.3	14
17	Gene Delivery by Liposomes. Israel Journal of Chemistry, 2013, 53, 737-747.	2.3	13
18	Alendronate Liposomes for Antitumor Therapy: Activation of γδT Cells and Inhibition of Tumor Growth. Advances in Experimental Medicine and Biology, 2012, 733, 165-179.	1.6	16

#	Article	IF	CITATIONS
19	Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clinical and Experimental Metastasis, 2012, 29, 441-456.	3.3	33
20	Liposomal alendronate for the treatment of restenosis. Journal of Controlled Release, 2012, 161, 619-627.	9.9	32
21	In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19347-19352.	7.1	121
22	Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. International Journal of Cancer, 2010, 126, 1749-1760.	5.1	48
23	Liposomal Simvastatin Attenuates Neointimal Hyperplasia in Rats. AAPS Journal, 2010, 12, 181-187.	4.4	24
24	Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. Journal of Controlled Release, 2010, 146, 182-195.	9.9	87
25	Route of administration-dependent anti-inflammatory effect of liposomal alendronate. Journal of Controlled Release, 2010, 148, 226-233.	9.9	28
26	Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2213-2218.	7.1	231
27	Biodistribution of antisense nanoparticles in mammary carcinoma rat model. Drug Delivery, 2010, 17, 408-418.	5.7	14
28	31P-NMR and Differential Scanning Calorimetry Studies for Determining Vesicle's Drug Physical State and Fraction in Alendronate Liposomes. Journal of Bioanalysis & Biomedicine, 2010, 02, .	0.1	6
29	Characterization of Monocytes-targeted Nanocarriers Biodistribution in Leukocytes in Ex-vivo and In-vivo Models. Nano Biomedicine and Engineering, 2010, 2, .	0.9	7
30	Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model. Human Reproduction, 2009, 24, 398-407.	0.9	67
31	Glossary of terms related to pharmaceutics (IUPAC Recommendations 2009). Pure and Applied Chemistry, 2009, 81, 971-999.	1.9	9
32	A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. Journal of Controlled Release, 2009, 133, 90-95.	9.9	238
33	Single and Double Emulsion Manufacturing Techniques of an Amphiphilic Drug in PLGA Nanoparticles: Formulations of Mithramycin and Bioactivity. Journal of Pharmaceutical Sciences, 2009, 98, 1452-1462.	3.3	52
34	Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo Characterization. AAPS Journal, 2008, 10, 505-515.	4.4	60
35	Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. Journal of Controlled Release, 2008, 132, 84-90.	9.9	115
36	Innate immunity has a dual effect on vascular healing: Suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis, 2008, 199, 41-46.	0.8	11

#	Article	IF	CITATIONS
37	Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell Culture Studies: Species-Dependent Susceptibility of Vascular Smooth Muscle Cells. Open Cardiovascular Medicine Journal, 2008, 2, 60-69.	0.3	4
38	Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine, 2007, 2, 545-553.	3.3	15
39	Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. Journal of Controlled Release, 2007, 117, 322-332.	9.9	38
40	Nano-Carriers of Drugs and Genes for the Treatment of Restenosis. Drugs and the Pharmaceutical Sciences, 2007, , 235-269.	0.1	0
41	Number-concentration of nanoparticles in liposomal and polymeric multiparticulate preparations: Empirical and calculation methods. Biomaterials, 2006, 27, 651-659.	11.4	42
42	Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. Journal of Controlled Release, 2006, 113, 23-30.	9.9	63
43	Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits. Journal of Biomedical Materials Research - Part A, 2006, 78A, 276-282.	4.0	10
44	Nanospheres of a Bisphosphonate Attenuate Intimal Hyperplasia. Journal of Nanoscience and Nanotechnology, 2006, 6, 3226-3234.	0.9	26
45	Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials, 2005, 26, 451-461.	11.4	66
46	Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. International Journal of Oncology, 2004, 24, 1235.	3.3	14
47	Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovascular Research, 2004, 64, 165-171.	3.8	32
48	Delivery and expression of pDNA embedded in collagen matrices. Journal of Controlled Release, 2004, 95, 309-320.	9.9	77
49	Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. International Journal of Oncology, 2004, 24, 1235-44.	3.3	20
50	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic and Medicinal Chemistry, 2003, 11, 2007-2018.	3.0	62
51	VEGFR-1–Selective VEGF Homologue PIGF Is Arteriogenic. Circulation Research, 2003, 92, 378-385.	4.5	284
52	Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits. Circulation, 2003, 108, 2798-2804.	1.6	100
53	Systemic Depletion of Macrophages by Liposomal Bisphosphonates Reduces Neointimal Formation Following Balloon-Injury in the Rat Carotid Artery. Journal of Cardiovascular Pharmacology, 2003, 42, 671-679.	1.9	65
54	Biodegradable Nanoparticles as Drug Delivery Systems for Parenteral Administration. , 2003, , .		0

4

#	Article	IF	CITATIONS
55	Macrophage Depletion by Clodronate-Containing Liposomes Reduces Neointimal Formation After Balloon Injury in Rats and Rabbits. Circulation, 2002, 106, 599-605.	1.6	221
56	Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-12951. Transplantation, 2002, 74, 1335-1341.	1.0	14
57	Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of αvβ3 receptor blockade. Atherosclerosis, 2002, 163, 269-277.	0.8	28
58	Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. Journal of Controlled Release, 2002, 83, 401-414.	9.9	49
59	Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. Journal of Controlled Release, 2002, 83, 389-400.	9.9	299
60	Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. Journal of Pharmaceutical Sciences, 2002, 91, 508-516.	3.3	14
61	Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Therapy, 2002, 9, 1607-1616.	4.5	62
62	Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. International Journal of Pharmaceutics, 2001, 220, 1-11.	5.2	25
63	Local delivery of mithramycin restores vascular reactivity and inhibits neointimal formation in in in injured arteries and vascular grafts. Journal of Controlled Release, 2001, 77, 167-181.	9.9	11
64	Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1434-1439.	2.4	53
65	Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite. Magnetic Resonance in Chemistry, 2000, 38, 11-16.	1.9	28
66	Long-chain functional bisphosphonates: synthesis, anticalcification, and antiresorption activity. Heteroatom Chemistry, 2000, 11, 470-479.	0.7	27
67	Treatment of restenosis by controlled-release delivery systems of tyrphostins. Drug Development Research, 2000, 50, 487-496.	2.9	1
68	Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Therapy, 2000, 7, 1896-1905.	4.5	348
69	Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Advanced Drug Delivery Reviews, 2000, 42, 175-195.	13.7	213
70	Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. Journal of Controlled Release, 2000, 65, 221-229.	9.9	85
71	Local Delivery of Platelet-Derived Growth Factor Receptor–Specific Tyrphostin Inhibits Neointimal Formation in Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 667-676.	2.4	61
72	The Effect of Topical Delivery of Novel Bisacylphosphonates in Reducing Alveolar Bone Loss in the Rat Model. Journal of Periodontology, 2000, 71, 1607-1612.	3.4	37

#	Article	IF	CITATIONS
73	A Peptide Prodrug Approach for Improving Bisphosphonate Oral Absorption. Journal of Medicinal Chemistry, 2000, 43, 3641-3652.	6.4	104
74	Long hain functional bisphosphonates: synthesis, anticalcification, and antiresorption activity. Heteroatom Chemistry, 2000, 11, 470-479.	0.7	1
75	Drug Delivery Systems for the Treatment of Restenosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2000, 17, 36.	2.2	23
76	Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharmaceutical Research, 1999, 16, 1399-1406.	3.5	19
77	Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. Journal of Controlled Release, 1999, 60, 129-142.	9.9	47
78	Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. , 1999, 60, 68-73.		163
79	Disposition of Alendronate Following Local Delivery in a Rat Jaw. Journal of Periodontology, 1999, 70, 893-895.	3.4	30
80	Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharmaceutical Research, 1998, 15, 606-613.	3.5	29
81	Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. Journal of Cellular Biochemistry, 1998, 68, 186-194.	2.6	51
82	Synthesis, Characterization, and Crystal Structure of Dicalcium Glutarylbis(phosphonate) Dihydrate: A Covalently Pillared Layer Structure with the Potential for Epitaxial Growth on Hydroxyapatite. Inorganic Chemistry, 1998, 37, 6485-6494.	4.0	20
83	PDGF-Receptor Tyrosine Kinase Blocker AG1295 Selectively Attenuates Smooth Muscle Cell Growth In Vitro and Reduces Neointimal Formation After Balloon Angioplasty in Swine. Circulation, 1998, 97, 1960-1969.	1.6	168
84	Preparation and Evaluation of Chitosan Microspheres Containing Bisphosphonates. Journal of Drug Targeting, 1997, 4, 371-380.	4.4	87
85	Effects of Continuous or Cyclic Administration of Pamidronate on the Skeleton in Intact and Oophorectomized Young Rats. Cells Tissues Organs, 1997, 159, 42-47.	2.3	1
86	In Vitro and In Vivo Effects of Tetrakisphosphonates on Bone Resorption, Tumor Osteolysis, Ectopic Calcification, and Macrophages. Journal of Pharmaceutical Sciences, 1997, 86, 283-289.	3.3	10
87	Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 53-63.	0.8	31
88	Site-specific delivery of colchicine in rat carotid artery model of restenosis. Journal of Controlled Release, 1997, 45, 65-73.	9.9	13
89	Biodegradable implant strategies for inhibition of restenosis. Advanced Drug Delivery Reviews, 1997, 24, 3-9.	13.7	22
90	Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis. Advanced Drug Delivery Reviews, 1997, 24, 53-62.	13.7	10

#	Article	IF	CITATIONS
91	Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. American Heart Journal, 1996, 131, 211-218.	2.7	17
92	Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis, 1996, 125, 171-182.	0.8	63
93	Effect of selective PDGF-receptor versus non-selective protein tyrosine kinase blockers on aortic smooth muscle cells (SMC's) and endothelial cells proliferation. Journal of the American College of Cardiology, 1996, 27, 255.	2.8	2
94	In vitro inhibition of membrane-mediated calcification by novel phosphonates. Calcified Tissue International, 1996, 58, 347-354.	3.1	12
95	Intrauterine administration of peptide drugs for systemic effect. Advanced Drug Delivery Reviews, 1995, 17, 179-190.	13.7	11
96	Pharmacokinetics and pharmacodynamics of trans-endometrial administered peptides and macromolecules. Advanced Drug Delivery Reviews, 1995, 17, 191-203.	13.7	12
97	Anticalcification and antiresorption effects of bisacylphosphonates. Bone, 1995, 16, 511-520.	2.9	42
98	Novel bisphosphonates for calcium-related disorders. Bone, 1995, 17, 601.	2.9	0
99	Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice-and once-daily treatment. Biopharmaceutics and Drug Disposition, 1994, 15, 45-52.	1.9	4
100	Continuous versus pulsatile administration of erythropoietin (EPO) via the uterus in anemic rats. International Journal of Pharmaceutics, 1994, 111, 197-202.	5.2	7
101	Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coronary Artery Disease, 1994, 5, 435-442.	0.7	35
102	Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty Journal of Clinical Investigation, 1994, 93, 1243-1249.	8.2	137
103	Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants. , 1994, , 259-268.		2
104	In-vitro and in-vivo models for the study of the relationship between hydrophilicity and calcification of polymeric and collageneous biornaterials. Clinical Materials, 1993, 13, 61-69.	0.5	7
105	A new route of drug administration: intrauterine delivery of insulin and calcitonin. Pharmaceutical Research, 1993, 10, 828-833.	3.5	25
106	In Vitro and In Vivo Inhibition of Hydroxyapatite Formation and Dissolution by Bisacylphosphonates and Bishydroxyiminophosphonates. Phosphorus, Sulfur and Silicon and the Related Elements, 1993, 76, 167-170.	1.6	5
107	Covalent Binding of Protamine by Glutaraldehyde to Bioprosthetic Tissue: Characterization and Anticalcification Effect. Biomaterials, Artificial Cells, and Immobilization Biotechnology: Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology, 1992, 20, 31-41	0.2	6
108	Calcification of polyurethane-based biomaterials implanted subcutaneously in rats: role of porosity and fluid absorption in the mechanism of mineralization. Journal of Materials Science: Materials in Medicine, 1992, 3, 272-277.	3.6	22

#	Article	IF	CITATIONS
109	Mechanical properties and histology of charge modified bioprosthetic tissue resistant to calcification. Biomaterials, 1992, 13, 353-356.	11.4	7
110	Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharmaceutical Research, 1992, 09, 1018-1023.	3.5	10
111	Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo. Pharmaceutical Research, 1992, 09, 143-148.	3.5	41
112	Controlled release of bisphosphonate from a biodegradable implant: Evaluation of release kinetics and anticalcification effect. Journal of Applied Biomaterials: an Official Journal of the Society for Biomaterials, 1992, 3, 23-28.	1.2	17
113	In Vitro and In Vivo Anticalcification Effects of Novel Bishydroxyiminophosphonates. Journal of Pharmaceutical Sciences, 1992, 81, 1004-1007.	3.3	20
114	Development of a new in vitro model for studying implantable polyurethane calcification. Biomaterials, 1991, 12, 397-405.	11.4	82
115	Characterization and anticalcification effects of implantable polyurethane matrices containing amorphous dispersion of bisphosphonic acid. Clinical Materials, 1991, 8, 33-42.	0.5	9
116	Prevention of bioprosthetic heart valve tissue calcification by charge modification: Effects of protamine binding by formaldehyde3. Journal of Biomedical Materials Research Part B, 1991, 25, 85-98.	3.1	47
117	Prevention of bacterial colonization on polyurethanein vitro by incorporated antibacterial agent. Journal of Biomedical Materials Research Part B, 1991, 25, 937-952.	3.1	44
118	Polymeric Controlled Release of Cardiovascular Drugs. , 1991, , 231-238.		6
119	The relationship between drug release rate, particle size and swelling of silicone matrices. Journal of Controlled Release, 1990, 12, 121-132.	9.9	41
120	Controlled release implants for cardiovascular disease. Journal of Controlled Release, 1990, 11, 245-254.	9.9	20
121	Controlled Release of Diphosphonates from Synthetic Polymers to Inhibit Calcification. Journal of Biomaterials Applications, 1987, 2, 266-289.	2.4	17
122	Controlled-Release Drug Delivery of Diphosphonates to Inhibit Bioprosthetic Heart Valve Calcification: Release Rate Modulation with Silicone Matrices Via Drug Solubility and Membrane Coating. Journal of Pharmaceutical Sciences, 1987, 76, 271-276.	3.3	69
123	Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. Journal of Controlled Release, 1986, 4, 181-194.	9.9	51
124	Inhibition of Bioprosthetic Heart Valve Calcification by Sustained Local Delivery of Ca and Na Diphosphonate via Controlled Release Matrices. ASAIO Transactions, 1986, 32, 587-590.	0.2	17
125	Clinical and microbiological effects of sustained release chlorhexidine in periodontal pockets. Journal of Clinical Periodontology, 1986, 13, 783-788.	4.9	66
126	Plaque Inhibition by Sustained Release of Chlorhexidine from Removable Appliances. Journal of Dental Research, 1985, 64, 1319-1321.	5.2	25

#	Article	IF	CITATIONS
127	Sustained Release Device Containing Metronidazole for Periodontal Use. Journal of Dental Research, 1984, 63, 1149-1153.	5.2	65
128	New sustained release dosage form of chlorhexidine for dental use: use for plaque control in partial denture wearers. Journal of Oral Rehabilitation, 1984, 11, 477-482.	3.0	14
129	Prevention of plaque accumulation by local application of a sustained release delivery system of chlorhexidine. Journal of Controlled Release, 1984, 1, 157-160.	9.9	5
130	New sustained release dosage form of chlorhexidine for dental use Journal of Periodontal Research, 1983, 18, 330-336.	2.7	87
131	New sustained release dosage form of chlorhexidine for dental use Journal of Periodontal Research, 1982, 17, 323-328.	2.7	106